AMSTERDAM – The World Health Organization's (WHO) first global report on hepatitis estimates 325 million people worldwide are living with chronic hepatitis B or C virus (HBV or HCV) infections, with the vast majority lacking access to life-saving testing and treatment. The situation has left millions of people at risk of a slow progression to chronic liver disease, cancer and death, it said.
AMSTERDAM – Despite the transformative impact of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV), reimbursement for the drugs still faces "considerable restrictions" in Europe, according to research presented Thursday at the International Liver Congress, suggesting that an early challenge for key drugmakers in the space, such as Gilead Sciences Inc. and Abbvie Inc., still endures.
AMSTERDAM – Debate about whether patients taking direct-acting antiviral (DAA) therapies for hepatitis C viral (HCV) infections are at risk of developing liver cancer after achieving sustained virologic response (SVR) continued unabashed Thursday at the European Association for the Study of the Liver's (EASL) annual International Liver Congress.
AMSTERDAM – Bristol-Myers Squibb Co.'s lead nonalcoholic steatohepatitis (NASH) candidate, BMS-986036, significantly reduced liver fat vs. placebo, meeting the primary endpoint of a phase II trial, the company reported during the International Liver Conference.
AMSTERDAM – NGM Biopharmaceuticals Inc., true to its fascination with the long-lasting effects of gastric bypass surgery and what President Jeff Jonker called the procedure's "fundamental rewiring" of metabolism, honed in on the liver de-fatting feats of its lead candidate, NGM282, during a presentation at the International Liver Conference.
AMSTERDAM – New data on Albireo Pharma Inc.'s A-4250, an ileal bile acid transport inhibitor, has shown its capacity to reduce high levels of serum bile acids (sBA), which are often associated with severe itching, or pruritus, and liver damage in children with the rare cholestatic liver disease progressive familial intrahepatic cholestasis (PFIC).
AMSTERDAM – A combination of two Abbvie Inc. drugs, glecaprevir and pibrentasvir (G/P, previously ABT-493/ABT-530), helped 95 percent of noncirrhotic patients infected with the world's most common genotype of chronic hepatitis C virus (HCV) achieve undetectable levels of the virus in their blood at 12 weeks (SVR12), according to new data from the study, ENDURANCE-3, presented Saturday at the International Liver Congress.
AMSTERDAM – The World Health Organization's (WHO) first global report on hepatitis estimates 325 million people worldwide are living with chronic hepatitis B or C virus (HBV or HCV) infections, with the vast majority lacking access to life-saving testing and treatment. The situation has left millions of people at risk of a slow progression to chronic liver disease, cancer and death, it said.
AMSTERDAM – Debate about whether patients taking direct-acting antiviral (DAA) therapies for hepatitis C viral (HCV) infections are at risk of developing liver cancer after achieving sustained virologic response (SVR) continued unabashed Thursday at the European Association for the Study of the Liver's (EASL) annual International Liver Congress.
AMSTERDAM – Despite the transformative impact of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV), reimbursement for the drugs still faces "considerable restrictions" in Europe, according to research presented Thursday at the International Liver Congress, suggesting that an early challenge for key drugmakers in the space, such as Gilead Sciences Inc. and Abbvie Inc., still endures.
